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Abstract
Background: Kallmann syndrome (KS) and CHARGE syndrome (CS) are rare her­
itable disorders in which anosmia and hypogonadotropic hypogonadism co-occur. 
KS is genetically heterogeneous with at least eight genes being involved in its patho­
genesis, whereas CS is caused by autosomal dominant mutations exclusively in 
CHD7 gene. The majority of CS-cases are sporadic and only few familial cases have 
been reported. In these families, mosaicism in one parent, as well as parent-to-child 
transmission of a CHD7 mutation, were described. The aim of the study: To report 
a paternal transmission of a variant in exon 32 of the CHD7 gene (c.6923C>T) in a 
familial case originally suggested to be affected by KS. Materials and methods: 
Five genes associated with KS were analyzed using Sanger sequencing and MLPA in 
a 17-year-old male. Results: The heterozygous variant leading to a change of amino- 
acid serine at position 2,308 to leucine was found in father his three children. Con­
clusion: Overall this report confirms the existence of KS without CS symptoms, 
caused by a mutation in a gene reported pathogenic only in CS.
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Introduction. Idiopathic hypogonado- 
tropic hypogonadism (IHH; OMIM 146110), 
one of the most commonly inherited forms of 
diminished functional activity of the gonads, 
results from deficient hypothalamic of gonad­
otropin releasing hormone (GnRH) release or 
action [1]. IHH patients present with absent or 
impaired sexual development due to sex- 
steroid-hormone deficiency, low serum levels 
of the pituitary gonadotropins follicle- 
stimulating hormone (FSH) and luteinizing 
hormone (LH), and infertility [1]. Kallmann 
syndrome (KS; OMIM 147950) is a combina­
tion of congenital hypogonadotropic hy­
pogonadism (HH; OMIM 146110) and de­
creased/absent sense of smell [2]. Anosmia, 
or the inability to smell, is the result of olfac­
tory bulb defects [3], whereas HH presents as 
absent or impaired pubertal maturation and is 
caused by GnRH deficiency [4]. KS accounts 
for about 50% to 60% of IHH [5] while forms 
of IHH present with normal olfaction (i.e. 
norm-osmic idiopathic HH: nIHH). KS is 
clinically and genetically very heterogeneous; 
phenotypic features may include additionally 
cleft lip/palate, hearing impairment, dental 
agenesis, limb anomalies, renal agenesis, and 
mirror movements [6]. The majority of KS 
cases (~60%) are sporadic; i.e. only one per­
son is affected in the family. In familial KS, 
autosomal recessive, autosomal dominant, 
and X-chromosomal recessive inheritance 
have been described [7]. Oligogenic mode of 
inheritance has also been suggested [8, 9]. At 
present, mutations in eight genes explain ap­
proximately 25-35% of KS cases. Heterozy­
gous loss-of-function mutations in the CHD7 
gene were identified in patients with nIHH, 
KS, and CHARGE syndrome (CS) [10, 11]. 
CS is a highly variable disorder in which con­
genital anomalies, multisensory impairment, 
and variable mental retardation can occur 
(OMIM 214800). CHARGE is an acronym 
for ocular coloboma, heart defects, choanal
atresia, retardation of growth and/or devel­
opment, genital hypoplasia and ear anomalies 
combined with deafness [12]. HH and anos­
mia are present in the majority of patients 
with CS [13]. Recently, it was proven that HH 
and anosmia may co-occur in CS, too [14], 
which means that KS can be considered as 
part of the phenotypic spectrum of CS. CHD7 
mutations are found in more than 90% of pa­
tients with typical CS [15].
Here we report a family with one pa­
tient with symptoms resembling KS however 
lacking CS symptoms, and with a novel het­
erozygous variant in exon 32 of the CHD7 




A 17-year-old male was the fifth child 
born to consanguineous Syrian healthy par­
ents with a remarkable family history (de­
layed puberty in the children). At birth of the 
index patient his mother and father were 34 
and 36 years old, respectively. The mother 
reported no history of infection during this 
pregnancy except for a slight hemorrhage at 
its beginning. After otherwise uncomplicated 
pregnancy and delivery, the index presented 
with micropenis and small testes (Tanner 
scale I, data not shown). At 17 years medical 
analyses showed an FSH (follicle stimulating 
hormone) level of 0.15 (normal value: 1.5 -  
12.4 mlU/ml), a LH (luteinizing hormone) 
level of 0.10 (normal value: 1.4 -  8.6 U/ml) 
and a testosterone total level of 1.9 (normal 
value: 2-8 nmol/l). The patient had a normal 
male 46,XY karyotype and azoospermia 
without AZF-chromosome microdeletions 
(results are not shown). Subsequent normal 
height (170 cm) and weight (68 kg), no colo­
boma, no choanal atresia, and no cardiovascu­
lar malformations. The patient suffered from 
anxiety, was nervous and slightly autistic. The 
patient’s older brother and sister (the second 
and third child of the family) also expired de­
layed puberty but disappeared spontaneously
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in the boy and in the girl after hormonal 
treatment for 1.5-2 years. The remainder 
family members were clinically healthy. The 
study was approved by the ethical committee 
of the Atomic Energy Commission, Damas­
cus, Syria. Informed consents were obtained 
from the father and other family members.
Genetic analysis
Genomic DNA was extracted from pe­
ripheral blood using QIAamp DNA Blood 
Mini Kit (Qiagen GMBH, Hilden, Germany). 
Sequencing of the following genes was per­
formed: Kallmann 1 KAL1 (ANOS;
NM_000216), Kallmann 2 FGFR1
(NM_23110.2), Kallmann 3 PROKR2
(NM_144773), Kallmann 4 PROK2
(NM_001126128), Kallmann 5 CHD7
(NM_017780). Analysis was performed step­
wise by Sanger-sequencing and analyses of 
deletions and duplications by Multiplex Liga­
tion-dependent Probe Amplification (MLPA, 
MRC-Holland).
Results. No mutations 
plications were found in 
NM_000216), FGFR1 
PROKR2 (NM_144773)
(NM_001126128). However, in CHD7 
(NM_017780) a novel heterozygous variant in 
exon 32 of the CHD7 gene (c.6923C>T) re­
sulting in an amino acid exchange 
(p.Ser2308Leu) was identified (Fig.) in pa­
tient, as well as in older 22 year old sister, 24 
year old brother and the father (Tab.).




Fig. Results of analyses of the CHD7-gene, exon 32.
Analysis of the CHD7-gene sequence was performed by JSI Seq Pilot software. 
Heterozygous sequence-variation was detected at position c.6923 (c.6923C>T, p.Ser2308Leu)
Table
Staitus of the variant c.6923C> " in the family
No. Family members age gender Variant c.6923C>T
1 father 52 M heterozygote
2 mother 50 F absent
3 child 1 27 M absent
4 child 2 24 M heterozygote
5 child 3 22 F heterozygote
6 child 4 20 F absent
7 child 5 17 M heterozygote
Discussion. KS is a unique form of IHH mental disorders with olfactory abnormalities
disease spectrum characterized by develop- being caused by congenital defects in GnRH
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secretion of varying degrees. The pulsatile 
secretion of GnRH is essential for the hypo­
thalamic pituitary-gonadal axis function [16]. 
Also, KS is a unique disease model to study 
the migration of GnRH neurons and the de­
velopment of human puberty. Some genes are 
necessary for the correct differentiation, mi­
gration, upstream signal regulation, and func­
tion of GnRH neurons in the embryonic peri­
od, which can lead to IHH [16]. Some genes 
that correctly differentiate embryonic GnRH 
neurons may be correlated with IHH, such as 
KAL-1, FGFR1, FGF8, PROKR2, PROK2, 
CHD7, NELF, WDR11, HS6ST1, KISS1R, 
KISS1, TAC3, TACR3, LEPR, LEP, PCSK1, 
GNRHR, GNRH1, SEMA3A, and NDN7 [16]. 
Mutations in these genes lead to certain de­
grees of clinical manifestations. Moreover, 
KS can be caused by genes such as KAL-1, 
FGFR1, PROKR2, PROK2, CHD7, and 
FGF8 [16]. Among them, the CHD7 mutation 
was only found in KS patients with the CS 
phenotype, suggesting that if  a patient was 
diagnosed with hypogonadism and anosmia, 
attention should be paid to the investigation of 
the presence of clinical characteristics of CS 
[16]. Here we report a paternally inherited 
new CHD7 mutation in a KS patient.
The CHD7 gene is located on chromo­
some 8q12.1, which encodes DNA-binding 
protein 7 of helicase in the chromatin region. 
This protein family has a unique functional 
domain binding site, including 2 N-terminal 
chromatin domains, 1 SWI2/SNF2-like ATP 
enzyme/solution helix domain, and 1 DNA 
binding domain. CHD7 protein complex is 
expressed in the olfactory epithelium, hypo­
thalamus, as well as the pituitary gland, sug­
gesting that this protein may play an im­
portant role in the development of the olfacto­
ry bulb and GnRH neuron migration. The ge­
netic pattern of CHD7 gene has not yet been 
fully understood, and may follow autosomal 
dominant inheritance, with its mutations ac­
counting for 6% of all IHH patients [17].
Jongmans et al. [10] identified 3/38 KS 
patients harboring de novo CHD7 mutations 
(2 stop-mutations and 1 missense) whereas 
the nIHH patients were negative for CHD7 
variants. However, all 3 KS patients with
CHD7 variants, upon additional phenotypic 
review, universally exhibited major CS fea­
tures. In contrast, Kim et al. [11] identified 
7/56 IHH patients (3KS, 4 nIHH) harboring 
CHD7 mutations (2 intronic mutations lead­
ing to exon skipping and 5 missense muta­
tions), all of whom lacked major CS pheno­
types, thus implicating CHD7 allelic variants 
as a cause of both KS and nIHH forms of IHH 
without CS features. In view of these conflict­
ing data as to whether CHD7 mutations are 
capable of causing KS or nIHH without full 
CS, Bergman et al. [18] examined 36 KS pa­
tients in whom they identified 3 with CHD7 
mutations (2 nonsense, and 1 de novo mis- 
sense). However, all three subjects displayed 
additional CS features, leading to their con­
clusion that CHD7 mutations do not cause 
isolated IHH. Laitinen et al. [19] revealed no 
CHD7 mutations in 30 Finnish KS patients. 
Jie et al. [16] found a family (two sons inher­
ited a mutation from his mother, but the 
mother and his younger son did not show 
clinical features of KS) suffering from KS and 
some clinical features of CS. Pedigree verifi­
cation can be achieved by CHD7 gene muta­
tion c.6571G>A. Hyung-Goo Kim et al. [11] 
examined 7/111 IHH/KS patients in whom 
they identified 7 CHD7 mutations (two splice 
and five missense), three unrelated probands 
with KS and four unrelated probands with 
IHH with CHD7 mutations, demonstrating 
that CHD7 is involved in either IHH or KS. 
However, Hyung-Goo Kim et al. [11] sug­
gested new evidence for a role of CHD7 in 
the pathophysiology of both normosmic IHH 
and KS patients without a CS phenotype.
The molecular basis for 70%-75% of 
IHH/KS patients remains unknown [11]. To 
date, only FGFR1 mutations have been re­
ported to cause either nIHH families or KS 
families. Although a homozygous PROKR2 
deletion was seen in a single family compris­
ing both normosmic and anosmic patients, 
this represents variable expressivity within the 
same family [11]. Interestingly, Hyung-Goo 
Kim et al. [11] found a one IHH and one KS 
patient, who both lack the CS phenotype, pos­
sess the same mutations (Ser834Phe and 
IVS65G/C) reported previously in patients 
with CS, further demonstrating the allelic re­
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lationship of both syndromes. The KS patient 
with the IVS65G/C mutation does not fulfill 
Blake’s criteria for CS, although she does 
have hearing impairment and cleft lip and 
palate. This also indicates that the effects of 
modifying genes may determine whether the 
patient has the more severe CS phenotype ra­
ther than the milder IHH/KS phenotype [11].
Overall, the family report confirms the 
existence of autosomal dominant inheritance 
of KS with lack of CS symptoms and a muta­
tion in the yet only reported pathogenic gene 
involved in CS. This heterozygous variant in 
exon 32 of the CHD7 gene (c.6923C>T), 
leading to a change of amino acid serine at 
position 2,308 to leucine devoid of any 
known functional domain, and therefore, it is 
unlikely to be a dominant negative form of 
the protein. Therefore, we hypothesize that 
this mutation represents a null allele, causing 
disease due to haploinsufficiency. This is in 
agreement with previous findings suggesting 
that a full genetic dosage is required for com­
plete function of CHD7 [18]. This novel vari­
ant in the present case was inherited from his 
father. Also, this variant was found in two 
subsequent children of his family. Moreover, 
this observation would draw the attention of 
the clinicians on the germline and familial 
responsible for the variable intrafamilial ex­
pression, suggesting a careful genetic coun­
seling.
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